The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Open accessAbstract
RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT: In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 3×
“Since then, the development of RNA interference (RNAi) technology (Napoli et al., 1990; Fire et al., 1998) has offered new routes for the studies of reverse genetics, specific gene expression and regulation, and targeted therapy with the potential to study, manipulate, and achieve control of disease.”
BackgroundThe C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 1×
“…that is hoped to increase delivery, membrane permeation efficiency, and biocompatibility to overcome both immunogenicity and endosomal escape (Alvarez-Erviti et al., 2011; van den Boorn et al., 2011; Shtam et al., 2013; Haney et al., 2015; Ha et al., 2016; Lu et al., 2018; Smith et al.,…”
BackgroundWightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292
Graphene oxide as a chemically tunable platform for optical applications
Loh, K. P., Bao, Q., Eda, G., & Chhowalla, M. (2010) · Nature Chemistry · doi:10.1038/nchem.907 · Cited by 3,340
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants
Hamilton, A. J., & Baulcombe, D. C. (1999) · Science · doi:10.1126/science.286.5441.950 · Cited by 3,041
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Processing of primary microRNAs by the Microprocessor complex
Denli, A. M., Tops, B. B. J., Plasterk, R. H. A., Ketting, R. F., & Hannon, G. J. (2004) · Nature · doi:10.1038/nature03049 · Cited by 2,784 · cited 10×
“In the cytosolic phase, pre-miRNAs are identified and further processed by RNase III endonuclease (Dicer) and the transactivating response RNA-binding protein (TRBP) (Denli et al., 2004; Okada et al., 2009; Ha and Kim, 2014) at the terminal loops of the hairpins to miRNA duplexes with two 3’ overhangs (Zhang et al.”
BackgroundInfluentialFunctional siRNAs and miRNAs exhibit strand bias
Khvorova, A., Reynolds, A., & Jayasena, S. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00801-8 · Cited by 2,645
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA
Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, B., Hayward, D. C., Ball, E. E., Degnan, B., Müller, P., et al. (2000) · Nature · doi:10.1038/35040556 · Cited by 2,565
Gene silencing by microRNAs: contributions of translational repression and mRNA decay
Huntzinger, E., & Izaurralde, E. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2936 · Cited by 2,339
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009
Intronic microRNA precursors that bypass Drosha processing
Ruby, J. G., Jan, C. H., & Bartel, D. P. (2007) · Nature · doi:10.1038/nature05983 · Cited by 1,722
Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells
Ohno, S.-I., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.180 · Cited by 1,666
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · cited 2×
“28 ASCVD and equivalent ASCVD risk, respectively, receiving 284 mg at day one and day ninety followed by a dose every six months thereafter for 540 days (Ray et al., 2020).”
BackgroundMethodThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443 · cited 8×
“With several endogenous sources of siRNA identified, a major source for RNAi studies uses exogenous siRNAs that are chemically synthesized and highly selectively to the mRNA transcripts of proteins previously considered to be “undruggable” by small molecule inhibitors (Setten et al., 2019; Smith et al., 2022).”
BackgroundInfluentialDrug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236 · cited 1×
“…cycle (e.g., c-MYC, E2F, CDK4, and CDK6) and apoptosis (e.g., BCL2 and SIRT1) as well as tumor-associated processes such as invasion (e.g., c-MET) (Hermeking, 2010; Misso et al., 2014). miR-34a has also shown antagonistic characteristics to cancer cell viability, stemness, metastasis, and…”
BackgroundThe chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions
Catalanotto, C., Cogoni, C., & Zardo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101712 · Cited by 1,190
A dicer-independent miRNA biogenesis pathway that requires Ago catalysis
Cheloufi, S., Dos Santos, C. O., Chong, M. M. W., & Hannon, G. J. (2010) · Nature · doi:10.1038/nature09092 · Cited by 1,149 · cited 2×
“However, Dicer/TRBP-independent pre-miRNAs require Ago2 to cleave the 30 strand and forming a pseudo-miRISC followed by 50 strand trimming to mature length (Cheloufi et al., 2010; Yang et al., 2010).”
BackgroundNair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141 · cited 1×
“Inclisiran is administered subcutaneously to patients to inhibit PCSK9 protein synthesis, decreasing the influence of PCSK9 on natural LDL recycling by binding to the 30UTR of PCSK9 mRNA and interfering with its translation (Nair et al., 2014; Khvorova, 2017; Lamb, 2021; Leqvio, 2021) (Fig.”
BackgroundOvercoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Napoli, C., Lemieux, C., & Jorgensen, R. (1990) · The Plant Cell · doi:10.2307/3869076 · Cited by 1,101
Single Processing Center Models for Human Dicer and Bacterial RNase III
Zhang, H., Kolb, F. A., Jaskiewicz, L., Westhof, E., & Filipowicz, W. (2004) · Cell · doi:10.1016/j.cell.2004.06.017 · Cited by 1,041
Exosomes: Therapy delivery tools and biomarkers of diseases
Barile, L., & Vassalli, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.020 · Cited by 1,038
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes.
Makris, K., & Spanou, L. (2016) · PubMed · Cited by 981
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J.-L., Kim, T.-Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 975
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
A Human snoRNA with MicroRNA-Like Functions
Ender, C., Krek, A., Friedländer, M. R., Beitzinger, M., Weinmann, L., Chen, W., Pfeffer, S., Rajewsky, N., & Meister, G. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.10.017 · Cited by 844
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
Berezikov, E., Chung, W.-J., Willis, J., Cuppen, E., & Lai, E. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.09.028 · Cited by 799
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6533 · Cited by 784
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S.-S. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 731
The Potential for microRNA Therapeutics and Clinical Research
Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 726
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Specific interference with gene function by double-stranded RNA in early mouse development
Wianny, F., & Zernicka-Goetz, M. (2000) · Nature Cell Biology · doi:10.1038/35000016 · Cited by 718
Mesoporous silica nanoparticles in medicine—Recent advances
Mamaeva, V., Sahlgren, C., & Lindén, M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.018 · Cited by 707
Kumar, P., Anaya, J., Mudunuri, S. B., & Dutta, A. (2014) · BMC Biology · doi:10.1186/s12915-014-0078-0 · Cited by 643
Valinezhad Orang, A., Safaralizadeh, R., & Kazemzadeh-Bavili, M. (2014) · International Journal of Genomics · doi:10.1155/2014/970607 · Cited by 641
Breaking down the barriers: siRNA delivery and endosome escape
Dominska, M., & Dykxhoorn, D. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.066399 · Cited by 630
Hypoxic Radiosensitization: Adored and Ignored
Overgaard, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7878 · Cited by 619
The Promise of MicroRNA Replacement Therapy
Bader, A. G., Brown, D., & Winkler, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2010 · Cited by 617
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Cochat, P., & Rumsby, G. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1301564 · Cited by 586
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Garrelfs, S. F., Frishberg, Y., Hulton, S. A., Koren, M. J., O’Riordan, W. D., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J. M., van’t Hoff, W. G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021712 · Cited by 531
Posttranscriptional Upregulation by MicroRNAs
Vasudevan, S. (2012) · WIREs RNA · doi:10.1002/wrna.121 · Cited by 510
Exosomes are natural carriers of exogenous siRNA to human cells in vitro
Shtam, T. A., Kovalev, R. A., Varfolomeeva, E. Y., Makarov, E. M., Kil, Y. V., & Filatov, M. V. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-88 · Cited by 499
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
The growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Yang, J.-S., Maurin, T., Robine, N., Rasmussen, K. D., Jeffrey, K. L., Chandwani, R., Papapetrou, E. P., Sadelain, M., O'Carroll, D., & Lai, E. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006432107 · Cited by 487
A Replication Cycle for Viroids and Other Small Infectious RNA's
Branch, A. D., & Robertson, H. D. (1984) · Science · doi:10.1126/science.6197756 · Cited by 485
A High-Resolution Structure of the Pre-microRNA Nuclear Export Machinery
Okada, C., Yamashita, E., Lee, S. J., Shibata, S., Katahira, J., Nakagawa, A., Yoneda, Y., & Tsukihara, T. (2009) · Science · doi:10.1126/science.1178705 · Cited by 484
Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018) · CNS Drugs · doi:10.1007/s40263-018-0578-5 · Cited by 471
Solomon, S. D., Adams, D., Kristen, A., Grogan, M., González-Duarte, A., Maurer, M. S., Merlini, G., Damy, T., Slama, M. S., Brannagan, T. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035831 · Cited by 462
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Kuscu, C., Kumar, P., Kiran, M., Su, Z., Malik, A., & Dutta, A. (2018) · RNA · doi:10.1261/rna.066126.118 · Cited by 409
Bissell, D. M., Anderson, K. E., & Bonkovsky, H. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608634 · Cited by 399
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
Self-citationATP-dependent human RISC assembly pathways
Yoda, M., Kawamata, T., Paroo, Z., Ye, X., Iwasaki, S., Liu, Q., & Tomari, Y. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1733 · Cited by 380
Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp106 · Cited by 369
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
Gebert, L. F. R., Rebhan, M. A. E., Crivelli, S. E. M., Denzler, R., Stoffel, M., & Hall, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt852 · Cited by 364
SiRNA delivery with exosome nanoparticles.
van den Boorn, J. G., Schlee, M., Coch, C., & Hartmann, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.1830 · Cited by 361 · cited 1×
“…that is hoped to increase delivery, membrane permeation efficiency, and biocompatibility to overcome both immunogenicity and endosomal escape (Alvarez-Erviti et al., 2011; van den Boorn et al., 2011; Shtam et al., 2013; Haney et al., 2015; Ha et al., 2016; Lu et al., 2018; Smith et al., 2022).”
BackgroundLeung, A. K. K., Hafez, I. M., Baoukina, S., Belliveau, N. M., Zhigaltsev, I. V., Afshinmanesh, E., Tieleman, D. P., Hansen, C. L., Hope, M. J., & Cullis, P. R. (2012) · The Journal of Physical Chemistry C · doi:10.1021/jp303267y · Cited by 360
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01473-6 · Cited by 359
siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury
Molitoris, B. A., Dagher, P. C., Sandoval, R. M., Campos, S. B., Ashush, H., Fridman, E., Brafman, A., Faerman, A., Atkinson, S. J., Thompson, J. D., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111204 · Cited by 337
2′-O-methyl-modified RNAs Act as TLR7 Antagonists
Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300240 · Cited by 336
tRNA-Derived Small RNA: A Novel Regulatory Small Non-Coding RNA
Li, S., Xu, Z., & Sheng, J. (2018) · Genes · doi:10.3390/genes9050246 · Cited by 335
Sequence-based design of bioactive small molecules that target precursor microRNAs
Velagapudi, S. P., Gallo, S. M., & Disney, M. D. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1452 · Cited by 327
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
Foster, D. J., Brown, C. R., Shaikh, S., Trapp, C., Schlegel, M. K., Qian, K., Sehgal, A., Rajeev, K. G., Jadhav, V., Manoharan, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.021 · Cited by 325 · cited 8×
“Vutrisiran consists of two fully modified strands of twenty-one- and twenty-three-nucleotides long with the latest version of the tri-GalNAc conjugate delivery platform, and it also contains thirty-five 2′-OMe, nine 2′-F, and contains six PS modifications at the strand ends (Foster et al., 2018; Weng et al., 2019).”
BackgroundMethodInfluentialEnhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics
Lönn, P., Kacsinta, A. D., Cui, X.-S., Hamil, A. S., Kaulich, M., Gogoi, K., & Dowdy, S. F. (2016) · Scientific Reports · doi:10.1038/srep32301 · Cited by 324
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321 · cited 3×
“) administered patisiran to off-target organs, and minimal drug accumulation after additional doses, suggesting patisiran siRNA to be cleared via nuclease activity (Coelho et al., 2013; Suhr et al., 2015; Adams et al., 2018).”
BackgroundMethodInfluentialYang, D., Buchholz, F., Huang, Z., Goga, A., Chen, C.-Y., Brodsky, F. M., & Bishop, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152327299 · Cited by 310
Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
(2013) · PubMed · Cited by 308
Recent Advances in miRNA Delivery Systems
Dasgupta, I., & Chatterjee, A. (2021) · Methods and Protocols · doi:10.3390/mps4010010 · Cited by 307
Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3847 · Cited by 306
Mirtrons: microRNA biogenesis via splicing
Westholm, J. O., & Lai, E. C. (2011) · Biochimie · doi:10.1016/j.biochi.2011.06.017 · Cited by 303
Discovering the first microRNA-targeted drug
Lindow, M., & Kauppinen, S. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208082 · Cited by 302
MicroRNA epigenetic signatures in human disease
Piletič, K., & Kunej, T. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1815-7 · Cited by 300
Scott, L. J., & Keam, S. J. (2021) · Drugs · doi:10.1007/s40265-020-01463-0 · Cited by 292
How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market.
Bonneau, É., Neveu, B., Kostantin, E., Tsongalis, G. J., & Guire, V. D. (2019) · PubMed Central · Cited by 288
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
From guide to target: molecular insights into eukaryotic RNA-interference machinery
Ipsaro, J. J., & Joshua-Tor, L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2931 · Cited by 281 · cited 2×
“In general, miRISC act through imperfect or partial complementarity to the 3’ untranslated region (3’UTR) of its target mRNA transcripts providing a wider range of target mRNA (Ender et al., 2008; Ha and Kim, 2014; Ipsaro and Joshua-Tor, 2015; Hasler et al., 2016; Patterson et al., 2017; Kuscu et al., 2018).”
BackgroundSelection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279 · cited 2×
“…specific ligands or by changing the physical conformation or chemical properties to increase uptake and endosomal escape into the cytosol (L€onn et al., 2016; Shum and Rossi, 2016; Chakraborty et al., 2017; Foster et al., 2018; Janas et al., 2018; Maguregui and Abe, 2020; Zhang et al., 2021a).”
BackgroundAnti-miRNA oligonucleotides: A comprehensive guide for design
Lima, J. F., Cerqueira, L., Figueiredo, C., Oliveira, C., & Azevedo, N. F. (2018) · RNA Biology · doi:10.1080/15476286.2018.1445959 · Cited by 276
RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase
Donze, O. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.10.e46 · Cited by 273
Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M., & Duell, P. B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013225 · Cited by 271
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
MicroRNA replacement therapy in cancer
Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28058 · Cited by 262
Naturally Occurring Exosome Vesicles as Potential Delivery Vehicle for Bioactive Compounds
Akuma, P., Okagu, O. D., & Udenigwe, C. C. (2019) · Frontiers in Sustainable Food Systems · doi:10.3389/fsufs.2019.00023 · Cited by 261
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D., Bissell, D. M., Desnick, R., Parker, C., Phillips, J., Bonkovsky, H. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1807838 · Cited by 259
Single-Stranded siRNAs Activate RNAi in Animals
Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.014 · Cited by 256
Evidence for the biogenesis of more than 1,000 novel human microRNAs
Friedländer, M. R., Lizano, E., Houben, A. J., Bezdan, D., Báñez-Coronel, M., Kudla, G., Mateu-Huertas, E., Kagerbauer, B., González, J., Chen, K. C., et al. (2014) · Genome Biology · doi:10.1186/gb-2014-15-4-r57 · Cited by 256
A brief history of RNAi: the silence of the genes
Sen, G. L., & Blau, H. M. (2006) · The FASEB Journal · doi:10.1096/fj.06-6014rev · Cited by 245
Challenges identifying efficacious miRNA therapeutics for cancer
Segal, M., & Slack, F. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1765770 · Cited by 244
Micro RNA mimicry blocks pulmonary fibrosis
Montgomery, R. L., Yu, G., Latimer, P. A., Stack, C., Robinson, K., Dalby, C. M., Kaminski, N., & van Rooij, E. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201303604 · Cited by 238
Recombinant RNA technology: the tRNA scaffold
Ponchon, L., & Dardel, F. (2007) · Nature Methods · doi:10.1038/nmeth1058 · Cited by 236
Hemophilia A and B: molecular and clinical similarities and differences
Castaman, G., & Matino, D. (2019) · Haematologica · doi:10.3324/haematol.2019.221093 · Cited by 236
Regulation of miRNA strand selection: follow the leader?
Meijer, H. A., Smith, E. M., & Bushell, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140142 · Cited by 233
Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival
Hand, T. W., Cui, W., Jung, Y. W., Sefik, E., Joshi, N. S., Chandele, A., Liu, Y., & Kaech, S. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003457107 · Cited by 228
A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies
Forterre, A., Komuro, H., Aminova, S., & Harada, M. (2020) · Cancers · doi:10.3390/cancers12071852 · Cited by 227
RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?
Meng, Z., & Lu, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00331 · Cited by 224
Cell Death Pathways Associated with Photodynamic Therapy: An Update
Kessel, D., & Oleinick, N. L. (2018) · Photochemistry and Photobiology · doi:10.1111/php.12857 · Cited by 223
Zhang, X., Goel, V., & Robbie, G. J. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1553 · Cited by 213
Recent progress in microRNA-based delivery systems for the treatment of human disease
Fu, Y., Chen, J., & Huang, Z. (2019) · ExRNA · doi:10.1186/s41544-019-0024-y · Cited by 211
The Risks of miRNA Therapeutics: In a Drug Target Perspective
Zhang, S., Cheng, Z., Wang, Y., & Han, T. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s288859 · Cited by 211
Definition and Diagnostic Criteria of Dry Eye Disease: Historical Overview and Future Directions
Shimazaki, J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-23475 · Cited by 210
Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing
Myers, J. W., Jones, J. T., Meyer, T., & Ferrell, J. E. (2003) · Nature Biotechnology · doi:10.1038/nbt792 · Cited by 208
MiR-122 in hepatic function and liver diseases
Hu, J., Xu, Y., Hao, J., Wang, S., Li, C., & Meng, S. (2012) · Protein & Cell · doi:10.1007/s13238-012-2036-3 · Cited by 208
Approaches for chemically synthesized siRNA and vector‐mediated RNAi
Amarzguioui, M., Rossi, J. J., & Kim, D. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.070 · Cited by 203
Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B. R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R. P., Erbe, D., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 201
MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
To, K. K., Tong, C. W., Wu, M., & Cho, W. C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i27.2949 · Cited by 198
MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases
He, Y., Huang, C., Lin, X., & Li, J. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.010 · Cited by 193
Meade, B. R., Gogoi, K., Hamil, A. S., Palm-Apergi, C., Berg, A. V. D., Hagopian, J. C., Springer, A. D., Eguchi, A., Kacsinta, A. D., Dowdy, C. F., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3078 · Cited by 191
Small Nucleolar RNAs Tell a Different Tale
Kufel, J., & Grzechnik, P. (2019) · Trends in Genetics · doi:10.1016/j.tig.2018.11.005 · Cited by 185
Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
Khvorova, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1614154 · Cited by 183
Backbone Modification of Nucleic Acids: Synthesis, Structure and Therapeutic Applications
Micklefield, J. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372391 · Cited by 182
Synthesis of RNA by In Vitro Transcription
Beckert, B., & Masquida, B. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-59745-248-9_3 · Cited by 181
Qiu, W., Park, J.-W., & Scholthof, H. B. (2002) · Molecular Plant-Microbe Interactions® · doi:10.1094/mpmi.2002.15.3.269 · Cited by 176
Habtemariam, B. A., Karsten, V., Attarwala, H., Goel, V., Melch, M., Clausen, V. A., Garg, P., Vaishnaw, A. K., Sweetser, M. T., Robbie, G. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1974 · Cited by 176
Shin, S. C., & Robinson‐Papp, J. (2012) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.21352 · Cited by 168
Role of miRNAs in immune responses and immunotherapy in cancer
Cortez, M. A., Anfossi, S., Ramapriyan, R., Menon, H., Atalar, S. C., Aliru, M., Welsh, J., & Calin, G. A. (2019) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22725 · Cited by 167
Building oligonucleotide therapeutics using non-natural chemistries
Wilson, C., & Keefe, A. D. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.10.001 · Cited by 165
Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit
Costales, M. G., Haga, C. L., Velagapudi, S. P., Childs-Disney, J. L., Phinney, D. G., & Disney, M. D. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11273 · Cited by 164
RNA therapy: Are we using the right molecules?
Yu, A.-M., Jian, C., Yu, A. H., & Tu, M.-J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 163
Self-citationIdentification of homologous microRNAs in 56 animal genomes
Li, S., Chan, W., Hu, L., Lai, C.-H., Hsu, C., & Lin, W. (2010) · Genomics · doi:10.1016/j.ygeno.2010.03.009 · Cited by 160
Small molecule recognition of disease-relevant RNA structures
Meyer, S. M., Williams, C. C., Akahori, Y., Tanaka, T., Aikawa, H., Tong, Y., Childs-Disney, J. L., & Disney, M. D. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00560f · Cited by 160
Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier
Lennox, K. A., Owczarzy, R., Thomas, D. M., Walder, J. A., & Behlke, M. A. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.46 · Cited by 158
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30368-9 · Cited by 158
Cardiac transthyretin amyloidosis
Dungu, J. N., Anderson, L. J., Whelan, C. J., & Hawkins, P. N. (2012) · Heart · doi:10.1136/heartjnl-2012-301924 · Cited by 153
PIWI Proteins and PIWI-Interacting RNA: Emerging Roles in Cancer
Han, Y.-N., Li, Y., Xia, S., Zhang, Y.-Y., Zheng, J.-H., & Li, W. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484541 · Cited by 151
Interplay between miRNAs and host genes and their role in cancer
Liu, B., Shyr, Y., Cai, J., & Liu, Q. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz002 · Cited by 137
The Lupus Autoantigen La Prevents Mis-channeling of tRNA Fragments into the Human MicroRNA Pathway
Hasler, D., Lehmann, G. J., Murakawa, Y., Klironomos, F., Jakob, L., Grässer, F. A., Rajewsky, N., Landthaler, M., & Meister, G. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.026 · Cited by 136
Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells
Babar, I., Czochor, J. R., Steinmetz, A., Weidhaas, J. B., Glazer, P. M., & Slack, F. J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.10.17681 · Cited by 131
The Principles of MiRNA-Masking Antisense Oligonucleotides Technology
Wang, Z. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-863-8_3 · Cited by 129
MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity
Xue, J., Chi, Y., Chen, Y., Huang, S., Ye, X., Niu, J., Wang, W., Pfeffer, L. M., Shao, Z.-M., Wu, Z.-H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.96 · Cited by 128
Ponchon, L., Beauvais, G., Nonin‐Lecomte, S., & Dardel, F. (2009) · Nature Protocols · doi:10.1038/nprot.2009.67 · Cited by 128
Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias
Besur, S. V., Hou, W., Schmeltzer, P. A., & Bonkovsky, H. L. (2014) · Metabolites · doi:10.3390/metabo4040977 · Cited by 116
Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs
Johannes, L., & Lucchino, M. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0716 · Cited by 114
Selective tissue targeting of synthetic nucleic acid drugs
Seth, P. P., Tanowitz, M., & Bennett, C. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125228 · Cited by 114
Lai, C.-J., Pursell, N. W., Gierut, J. J., Saxena, U. H., Zhou, W. L., Dills, M., Diwanji, R., Dutta, C., Koser, M. L., Nazef, N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.016 · Cited by 112
An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
Machin, N., & Ragni, M. V. (2018) · Journal of Blood Medicine · doi:10.2147/jbm.s159297 · Cited by 111
Nanoscale delivery systems for microRNAs in cancer therapy
Boca, S., Gulei, D., Zimța, A., Onaciu, A., Magdo, L., Țigu, A. B., Ionescu, C., Irimie, A., Buiga, R., & Berindan‐Neagoe, I. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03317-9 · Cited by 110
Agarwal, S., Simon, A. R., Goel, V., Habtemariam, B. A., Clausen, V. A., Kim, J. B., & Robbie, G. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1802 · Cited by 110
The Ligand Nanoparticle Conjugation Approach for Targeted Cancer Therapy
Karra, N., & Benita, S. (2011) · Current Drug Metabolism · doi:10.2174/138920012798356899 · Cited by 102
Exosome-based small RNA delivery: Progress and prospects
Lu, M., Xing, H., Xun, Z., Yang, T., Ding, P., Cai, C., Wang, D., & Zhao, X. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.07.008 · Cited by 97 · cited 7×
“Using exosomes over traditional NPs provides a more advantageous natural means of drug delivery that are hoped to increase delivery, membrane permeation efficiency, and biocompatibility to overcome both immunogenicity and endosomal escape (Alvarez-Erviti et al., 2011; van den Boorn et al., 2011; Shtam et al., 2013; Ha…”
BackgroundInfluentialTivanisiran, a novel siRNA for the treatment of dry eye disease
Moreno‐Montañés, J., Bleau, A., & Jiménez, A. I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1457647 · Cited by 97
Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasion
Patterson, D. G., Roberts, J. T., King, V. M., Houserova, D., Barnhill, E. C., Crucello, A., Polska, C. J., Brantley, L. W., Kaufman, G. C., Nguyen, M., et al. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0032-8 · Cited by 95
Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs
Nguyen, D.-D., & Chang, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010065 · Cited by 95
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 95
Self-citationAcute hepatic porphyrias: Current diagnosis & management
Anderson, K. E. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.07.002 · Cited by 94
Ventura, P., Bonkovsky, H. L., Gouya, L., Aguilera, P., Bissell, D. M., Stein, P. E., Balwani, M., Anderson, D. K. E., Parker, C., Kuter, D. J., et al. (2021) · Liver International · doi:10.1111/liv.15090 · Cited by 86
Thompson, J. D., Kornbrust, D. J., Foy, J. W.-D., Solano, E. C. R., Schneider, D. J., Feinstein, E., Molitoris, B. A., & Erlich, S. S. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0371 · Cited by 85
Frishberg, Y., Deschênes, G., Groothoff, J. W., Hulton, S., Magen, D., Harambat, J., Hoff, W. V., Lorch, U., Milliner, D. S., Lieske, J. C., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14730920 · Cited by 85
To, K. K. W. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-99 · Cited by 84
Pan, Y.-Z., Zhou, A., Hu, Z., & Yu, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052092 · Cited by 81
Self-citationChen, Q., Wang, W.-P., Zeng, S., Urayama, S., & Yu, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv228 · Cited by 81
Self-citationYu, A., Tian, Y., Tu, M., Ho, P. Y., & Jilek, J. L. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067470 · Cited by 81
Self-citationSas, D. J., Magen, D., Hayes, W. N., Shasha‐Lavsky, H., Michael, M., Schulte, I., Sellier‐Leclerc, A., Lu, J., Seddighzadeh, A., Habtemariam, B. A., et al. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.024 · Cited by 81
Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine
Smith, E. S., Whitty, E., Yoo, B., Moore, A. V., Sempere, L. F., & Medarova, Z. O. (2022) · Cancers · doi:10.3390/cancers14061588 · Cited by 81
Xu, C., Haque, F., Jasinski, D. L., Binzel, D. W., Shu, D., & Guo, P. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.043 · Cited by 79
Obici, L. P., Berk, J. L., González‐Duarte, A., Coelho, T., Gillmore, J. D., Schmidt, H., Schilling, M., Yamashita, T., Labeyrie, C., Brannagan, T. H., et al. (2020) · Amyloid · doi:10.1080/13506129.2020.1730790 · Cited by 78
Recent Progress in Chemically Modified siRNAs
Gaglione, M., & Messere, A. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955710791384036 · Cited by 76
Bezawy, R. E., Tinelli, S., Tortoreto, M., Doldi, V., Zuco, V., Folini, M., Stucchi, C., Rancati, T., Valdagni, R., Gandellini, P., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1060-z · Cited by 75
Li, X., Tian, Y. E., Tu, M., Ho, P. Y., Batra, N., & Yu, A. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.12.002 · Cited by 74
Self-citationKallend, D., Stoekenbroek, R., He, Y., Smith, P. F., & Wijngaard, P. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.01.001 · Cited by 73
Bioengineering of noncoding RNAs for research agents and therapeutics
Ho, P. Y., & Yu, A. (2016) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1324 · Cited by 73
Self-citationEmerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 73
Yi, W., Tu, M., Liu, Z., Zhang, C., Batra, N., Yu, A.-X., & Yu, A. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.001 · Cited by 72
Self-citationEfficient and specific gene knockdown by small interfering RNAs produced in bacteria
Huang, L., Jin, J., Deighan, P., Kiner, E., McReynolds, L. A., & Lieberman, J. (2013) · Nature Biotechnology · doi:10.1038/nbt.2537 · Cited by 70
González‐Duarte, A., Berk, J. L., Quan, D., Mauermann, M. L., Schmidt, H., Polydefkis, M. J., Waddington‐Cruz, M., Ueda, M., Conceição, I. M., Kristen, A. V., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09602-8 · Cited by 70
Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge
Jung, J., Yeom, C., Choi, Y., Kim, S., Lee, E. J., Park, M. J., Kang, S. W., Kim, S. B., & Chang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4827 · Cited by 69
MicroRNAs are important regulators of drug resistance in colorectal cancer
Zhang, Y., & Wang, J. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0308 · Cited by 69
Pallet, N., Karras, A., Thervet, É., Gouya, L., Karim, Z., & Puy, H. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx146 · Cited by 69
Wang, W., Ho, P. Y., Chen, Q., Addepalli, B., Limbach, P. A., Li, M., Wu, W., Jilek, J. L., Qiu, J., Zhang, H., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225631 · Cited by 67
Self-citationBioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy
Ho, P. Y., Duan, Z., Batra, N., Jilek, J. L., Tu, M., Qiu, J.-X., Hu, Z., Wun, T., Lara, P. N., White, R. D., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.247775 · Cited by 67
Self-citationFast production of homogeneous recombinant RNA—towards large-scale production of RNA
Nelissen, F. H. T., Leunissen, E. H. P., van de Laar, L., Tessari, M., Heus, H. A., & Wijmenga, S. S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks292 · Cited by 65
Umeh-Garcia, M. C., Simion, C., Ho, P.-Y., Batra, N., Berg, A. L., Carraway, K. L., Yu, A., & Sweeney, C. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0656 · Cited by 62
Self-citationAdvances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
To, K. K. W., Fong, W., Tong, C. W. S., Wu, M., Yan, W., & Cho, W. C. S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1690449 · Cited by 62
Li, M.-M., Addepalli, B., Tu, M., Chen, Q., Wang, W.-P., Limbach, P. A., LaSalle, J. M., Zeng, S., Huang, M., & Yu, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064493 · Cited by 59
Self-citationVarzideh, F., Kansakar, U., Donkor, K., Wilson, S. M., Jankauskas, S. S., Mone, P., Wang, X., Lombardi, A., & Santulli, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.863238 · Cited by 58
Above the Epitranscriptome: RNA Modifications and Stem Cell Identity
Morena, F., Argentati, C., Bazzucchi, M., Emiliani, C., & Martino, S. (2018) · Genes · doi:10.3390/genes9070329 · Cited by 57
Cited by
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Wang, Y., Tu, M.-J., & Yu, A.-M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1423416 · Cited by 21
Self-citation
Metadata
- Authors
- Traber, G. M., & Yu, A.-M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 384
- Issue
- 1
- Pages
- 133-154
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W4282944269
- Cited by
- 291
- References
- 244
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.